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ABSTRACT: The bicyclic boronate VNRX-5133 (taniborbactam) is a new type of β-lactamase inhibitor in clinical
development. We report that VNRX-5133 inhibits serine-β-lactamases (SBLs) and some clinically important metallo-β-
lactamases (MBLs), including NDM-1 and VIM-1/2. VNRX-5133 activity against IMP-1 and tested B2/B3 MBLs was lower/
not observed. Crystallography reveals how VNRX-5133 binds to the class D SBL OXA-10 and MBL NDM-1. The
crystallographic results highlight the ability of bicyclic boronates to inhibit SBLs and MBLs via binding of a tetrahedral (sp3)
boron species. The structures imply conserved binding of the bicyclic core with SBLs/MBLs. With NDM-1, by crystallography,
we observed an unanticipated VNRX-5133 binding mode involving cyclization of its acylamino oxygen onto the boron of the
bicyclic core. Diﬀerent side-chain binding modes for bicyclic boronates for SBLs and MBLs imply scope for side-chain
optimization. The results further support the “high-energy-intermediate” analogue approach for broad-spectrum β-lactamase
inhibitor development and highlight the ability of boron inhibitors to interchange between diﬀerent hybridization states/
binding modes.
■ INTRODUCTION
β-Lactamase-catalyzed hydrolysis is the most important
resistance mechanism for β-lactams, which comprise the most
important class of antibacterials (Figure 1A, top).1 Inhibitors of
one of the two mechanistic classes of β-lactamases, the
nucleophilic serine-β-lactamases (SBLs),2 are established
drugs for use in combination with an appropriate β-lactam
antibiotic partner (Figure 1B, bottom). The well-established
SBL inhibitors (clavulanic acid,3,4 sulbactam,5 tazobactam6)
only inhibit a subset of SBLs (Ambler class A and some class C
enzymes, but not typically class D enzymes) and are increasingly
susceptible to evolved resistance, including via bacterial
production of extended-spectrum serine-β-lactamases
(ESBLs). The same issues are compromising the use of
carbapenems, whichmanifest both antibacterial and β-lactamase
inhibition properties.7,8
The clinical importance of the second mechanistic class of β-
lactamases, i.e., the zinc-ion-dependent metallo-β-lactamases
(MBLs), which have a diﬀerent fold/evolutionary origin to the
SBLs, is growing.9 This is of particular concern because MBLs
catalyze the eﬃcient hydrolysis of nearly all β-lactam classes,
with the exception of the monobactams, which are not currently
hydrolyzed by MBLs at a clinically relevant rate.10 The
vulnerability of the β-lactams to β-lactamases has long
stimulated interest in developing non-β-lactam inhibitors of
penicillin-binding proteins (PBPs) and β-lactamases. These
studies resulted in the development of avibactam,11,12 which,
unlike (at least most) “traditional” β-lactam inhibitors that act
irreversibly to form acyl-enzyme complexes, inhibits class A, C,
and some class D SBLs by reversible formation of an acyl-
enzyme-type complex via reaction of its diazabicyclooctane core.
However, avibactam does not inhibit MBLs;13 moreover, there
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is evidence that SBLs and MBLs have potential to evolve to
hydrolyze it.14
There is thus interest in the development of non-acylating
inhibitors of β-lactamases and PBPs.With this objective inmind,
multiple approaches and compounds have been explored, most
with relatively little success. In pioneering work, acyclic boronic
acids have been developed as multiple myeloma drugs, targeting
human proteasomes, which employ nucleophilic threonine
catalysis.16 After a long gestation period, boronic acids/boronate
esters have emerged as β-lactamase inhibitors with considerable
clinical potential.17−20 Boronate-based inhibitors are of
mechanistic interest as, in their tetrahedral (sp3-hybridized)
forms, they are proposed to be analogues of the high-energy
“tetrahedral” intermediates present in the catalytic cycle of the
nucleophilic serine enzymes, such as SBLs (Figure 1B) and
PBPs, as well as MBLs (Figure 1C).21,22 It has also been
proposed that boron in its sp2-hybridized form can mimic the β-
lactam carbonyl group of substrates, which β-lactamases bind
highly eﬃciently.23
Recent work has led to the ﬁrst clinical introduction of a
boronic acid-based SBL inhibitor, vaborbactam (formerly
RPX7009), for use in combination with the carbapenem
meropenem.24,25 Whilst the early boronic acid SBL inhibitors
are apparently predominantly acyclic in solution, vaborbactam
adopts a monocyclic boronate structure, as observed at the
active site of an SBL (CTX-M-15).24 Vaborbactam, however,
Figure 1. β-Lactam antibacterials, β-lactamase inhibitors in clinical use, outline mechanisms for serine- and metallo-β-lactamase (SBL and MBL)
catalysis, and bicyclic boronates in research and development. (A) Major classes of β-lactam antibiotics and SBL inhibitors currently in clinical use,
including the clinically approved “monocyclic” boron-containing inhibitor vaborbactam (which has little MBL activity15); mode of action of (B) SBLs
and (C) MBLs, exempliﬁed by hydrolysis of a carbapenem. Note that the hydrolyzed carbapenem products can be produced in diﬀerent tautomeric
forms. (D) Note that the ability of boronate inhibitors (e.g., VNRX-5133) to interchange between sp2 and sp3 forms can enable them to mimic both
substrates (sp2 carbonyl) and the ﬁrst tetrahedral intermediate (sp3). Selected examples of bicyclic boronates from research and development are
shown.
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has limited SBL coverage and only moderately inhibits
MBLs.15,26 By contrast, recent studies have indicated that
bicyclic boronates can inhibit a broader range of SBLs and,
importantly, some B1 subfamily MBLs.27,28
The potential of bicyclic boronates to act as dual action
inhibitors of SBLs and MBLs is reported in the academic27−29
and patent literature.30 Taniborbactam (VNRX-5133) is now in
phase 3 clinical trials as a relatively broad-spectrum β-lactamase
inhibitor. However, while its ability to extend the activity of β-
lactam antibiotics against SBL- and MBL-harboring bacteria is
reported,31−33 the breadth of its activity versus isolated β-
lactamases has been unclear. There are no reported structures of
VNRX-5133 complexed with SBLs or MBLs in the PDB
database. To address these issues, we synthesized VNRX-5133
and tested it for inhibition against a panel of SBLs and MBLs.
The results support the potential of bicyclic boronates for broad-
spectrum β-lactamase inhibition. Together with previous
studies, they also illustrate how the ability of boron to readily
interchange between diﬀerent hybridization states and binding
modes in water can help to enable potent inhibition.
■ RESULTS AND DISCUSSION
Synthesis. VNRX-5133 was synthesized via a modiﬁed
version of the reported30 stereocontrolled route in 11 steps from
2-methoxy-3-methylbenzoic acid 1 via Matteson homologa-
tion34 (Figure 2A).
Figure 2. Synthesis andNMR analysis of VNRX-5133. (A) Reagents and conditions: (a) oxalyl chloride, cat. DMF, CH2Cl2, room temperature (rt), 90
min and then 2-methylpropan-2-ol, 40 °C, 18 h; (b)N-bromosuccinimide, benzoyl peroxide, CCl4, reﬂux, UV, 5 h; (c) bis[(+)-pinanediolato]diboron,
Pd(dppf)Cl2, KOAc, 1,4-dioxane, 95 °C, 16 h; (d) CH2Cl2, tetrahydrofuran (THF), n-BuLi,−100 °C, 45min and then 4 in THF, ZnCl2,−95 °C to rt,
overnight; (e) lithium bis(trimethylsilyl)amide, THF,−100 °C to−78 °C, 2 h; (f)MeOH, THF,−10 °C to rt, 1 h; (g) K2CO3, 1:1 CH2Cl2/H2O, rt, 1
h and then 2-(boc-amino)ethyl bromide, benzyltriethylammonium chloride, reﬂux, 18 h; (h) di-tert-butyl dicarbonate, N,N-diisopropylethylamine,
reﬂux, 16 h; (i) LiOH·H2O, 1:2:1 THF/EtOH/H2O, rt, 5 h; (j) 11, triethylamine, PyBOP and then crude 7, rt, 75 min; (k) BCl3, CH2Cl2,−78 °C, 1 h.
(B) 1H NMR (600 MHz) of high-performance liquid chromatography (HPLC)-puriﬁed VNRX-5133 in D2O.
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The requisite (+)-pinanediol boronate precursor 4 (87%) was
prepared according to reported procedures.27 Stereoselective
one-carbon homologation of 4 using in situ generated
dichloromethyllithium35 gave (S)-chloride 5. Initial yields
after chromatographic puriﬁcation were low. Following
optimization, 5 was routinely obtained in improved yield
(55−61%) in high diastereomeric purity (d.r., <98%, 1H
NMR).36 Reaction of 5 with lithium bis(trimethylsilyl)amide
at −90 °C gave bis(trimethylsilyl)-protected amine 6 with
inversion of conﬁguration. To avoid decomposition, crude N-6
was not separated and immediately treated with stoichiometric
anhydrous methanol (−10 °C to room temperature, THF) to
give amine 7.
The desired side chain carboxylic acid with the trans
stereochemistry 11 was prepared from commercial ethyl 2-
(trans-4-aminocyclohexyl) acetate hydrochloride 8 in three
steps. Initial attempts to install the desired ethane-1,2-diamine
moiety via N-alkylation were unproductive, possibly due to the
low solubility of 8 in the tested organic solvents. Biphasic
conditions (1:1, CH2Cl2:H2O) employing 5 mol% benzyltrie-
thylammonium chloride as a phase-transfer catalyst gave 9
(49%) following chromatography, which was Boc-protected to
give ethyl ester 10 (82%). Saponiﬁcation followed by ion-
exchange chromatography (Amberlite H-120) gave 11 (67%).
The formation of the amide linking 7 and 11 was achieved
using (benzotriazole-1-yloxy)tripyrrolidinophosphonium hexa-
ﬂuorophosphate (PyBOP)37 to give 12 in moderate yield
(34%). One-pot cleavage of the Boc, tert-butyl, methyl ether
protecting groups, and the chiral auxiliary using BCl3 (−78 °C,
CH2Cl2) followed by acidic workup (likely aiding the
spontaneous bicyclization) gave VNRX-5133 (13) (42%)
following HPLC puriﬁcation. VNRX-5133 (13) was thus
prepared in 3% overall yield over 6 linear steps (excluding
steps e and f, Figure 2A, where intermediates were not isolated).
The route described here represents an improvement for the
asymmetric synthesis of VNRX-5133 compared to that
reported,30 with the number of steps being cut from 16 to 11.
There is, however, clear scope for further optimization.
Biochemical Evaluation. We screened VNRX-5133 for
activity against a panel of clinically relevant SBLs and MBLs
(Table 1) using an established method involving hydrolysis of
the “ﬂuorogenic” cephalosporin probe FC538 or meropenem for
CphA.27 In conference reports, VNRX-5133 has been reported
to inhibit both SBLs and MBLs.31,33,39 Consistent with this and
our previously reported results on the inhibition of all classes of
β-lactamases by structurally related (bi)cyclic boronates,27−29
VNRX-5133 manifests submicromolar half-maximal inhibitory
concentration (IC50) values (0.53−0.008 μM) against all major
classes of clinically relevant β-lactamases tested, with particularly
potent activity, i.e., in the subnanomolar range (IC50∼ 0.5 nM),
against the Verona-integron-encoded MBL-2, VIM-2. Notably,
VNRX-5133 was less active against the clinically important
imipenemase (IMP)-1 B1 MBL (IC50 ∼ 2.51 μM) and the B2
MBL from Aeromonas hydrophila CphA (CphA, IC50 ∼ 2.51
μM), nor did it inhibit subclass B3 MBL L1 from
Stenotrophomonas maltophilia. The comparison of IC50 values
reveals that VNRX-5133 (taniborbactam) is 50 to >50 000-fold
more potent against the clinically relevant MBLs compared to
vaborbactam15 (VNRX-5133 is, in general, more potent than the
structurally related bicyclic boronate CB226,27 against the same
enzymes). Variation in the pre-incubation times of VNRX-5133
with subclass B1 MBL NDM-1 did not result in diﬀerent IC50
values (Supporting Information Table S2 and Figure S33), thus
supporting the case for the reversible inhibition by VNRX-5133,
as observed for related bicyclic boronate inhibitors.29,40
Notably, improved inhibition with respect to vaborbactam is
also observed for VNRX-5133 against the class A narrow-
spectrum β-lactamase TEM-116 (500-fold increase) and for the
tested class D SBLs (a 10- to 2000-fold increase, Table 1). In
particular, VNRX-5133 manifests moderate inhibition of the
narrow-spectrum oxacillinase OXA-10 (IC50 ∼ 0.234 μM),
which is not inhibited by vaborbactam (Table 1). Only
moderate inhibition of the OXA-48 carbapenemase was
observed (IC50 ∼ 0.537 μM). Overall, these results support
the proposal that VNRX-5133 possesses an unusually broad-
spectrum inhibitory activity against Ambler Class A (ESBLs), B
(NDM and VIM), C (AmpC from P. aeruginosa) and, to a
somewhat lesser extent, D (OXA) β-lactamases. Nonetheless,
the lower activity of VNRX-5133, in particular, against the
subclass B1 MBL IMP-1, as well as the tested B2/B3 MBLs
implies that there is scope for further optimization of this new
inhibitor class.
Crystallography. To investigate the binding mode of
VNRX-5133 to β-lactamases, we initiated crystallographic
analyses and obtained structures of it in complex with the
class D SBL OXA-10 and the B1 subclass MBL NDM-1, at
resolutions of 2.17 Å (space group: P212121) and 1.51 Å (space
group: P212121), respectively. In each structure, there are two
chains (A/B) in the asymmetric unit.
Table 1. Activities of VNRX-5133 versus representative serine- and metallo-β-lactamasesa
class enzyme VNRX-5133 IC50 (μM) vaborbactam
15 IC50 (μM) CB2
27,28 IC50 (μM)
SBL A TEM-116 0.12 6 0.00327
MBLs B1 IMP-1 2.51 126 127
B1 NDM-1 0.01 631 0.02927
B1 VIM-1 0.0079 398 0.08528
B1 VIM-2 0.0005 316 0.00327
B2 CphA 2.51 631 >10027
B3 L1 >10 336 not inhibited41
SBL C AmpC (P. aeruginosa) 0.301 5 0.1228
SBLs D OXA-10 0.234 >400 not available
D OXA-10b 0.645 >400 5.128
D OXA-48 0.537 25 not available
D OXA-48b 2.39 32 2.628
aIC50 values of VNRX-5133 against a panel of SBLs and MBLs (see Supporting Information Table S1 for error analysis). SBL, serine-β-lactamase;
MBL, metallo-β-lactamase. bThese assays were run in the presence of 100 mM aqueous sodium bicarbonate.
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After soaking of an NDM-1 crystal with VNRX-5133, there
was clear Fo−Fc density corresponding to bound VNRX-5133 in
the active site in both chains A and B. Unexpectedly, the electron
density (Figure 3) indicated the presence of a tricyclic form of
VNRX-5133 (Figure 3B, and Supporting Information Figure
S2A), which was reﬁned at full occupancy in chain B (with an
average B-factor of 18.02 Å2). In chain A, a mixture of both the
bicyclic (as solely observed with OXA-10) (Figure 3A) and
tricyclic forms was modeled (at occupancies of 0.6 and 0.4,
respectively). The ethylamino atoms of the VNRX-5133 side
chain in both chains A and B lacked observable electron density
and were removed in the ﬁnal model. The tricyclic structure is
probably formed by cyclization of the side chain amide oxygen
onto the boron. Although there is no obvious basic amino acid
residue close enough to the side chain amide to catalyze this
reaction manifested in the crystal structure, this type of reaction
has precedent in synthetic chemistry.42
For both bicyclic and tricyclic forms with NDM-1, the bicyclic
“boronate core”, including the aryl carboxylate, adopts nearly
identical binding modes (Figure 3C). Notably, binding of
VNRX-5133 to NDM-1 increases the Zn1−Zn2 distance from
∼3.6 Å (e.g., PDB ID: 5ZGZ43) to 4.3 Å (in both chains A and
B); a similar increase has been observed on binding/reaction of
the antibiotic ampicillin with NDM-1 (PDB ID: 5ZGE43) and
on binding of CB2 to VIM-2.43 Such changes in the positioning
of metal ions induced by inhibitor−substrate interactions in β-
lactamase catalysis have also been observed with extended X-ray
absorption ﬁne structure (EXFAS) spectroscopy studies, as
shown in the case of the subclass B3 MBL L1 from S.
maltophilia44 and with other metallo-enzymes (see e.g.,45−47); it
may also be that the extent of suchmetal ion translocations is not
fully reﬂected in crystallographic compared to solution studies.
It should also be noted that the precipitants used in
crystallography experiments for NDM-1:VNRX-5133 and
OXA-10:VNRX-5133 structures were at pH 5.8 and pH 8.0,
respectively.
One boron-bound oxygen eﬀectively bridges the two active
site zinc ions in NDM-1 but is closer to Zn1 (1.9 Å) than Zn2 (3
Å). The boron-bound oxygen that “becomes” part of the 5-
membered ring of the tricyclic VNRX-5133 (Figure 3B) is
positioned to make a signiﬁcantly weaker interaction with Zn2
(2.8 Å) than Zn1 and is positioned almost identically to the same
boron-bound oxygen in the bicyclic VNRX-5133 structure
(Figure 3C). For comparison, CB2 binding to VIM-2 results in
interactions of the boron-bound oxygens of 2.6 and 1.9 Å to
Zn2.27 A number of other interactions of VNRX-5133 are
conserved with respect to other bicyclic boronates (i.e., CB2 and
others27−29), including that of the aryl carboxylate with Zn2 and
Lys224 and the “endocyclic” boronate ester oxygen with Zn2.
The L3 loop, which is proposed to be involved in binding
Figure 3. Structural basis of serine- and metallo-β-lactamase inhibition by VNRX-5133. (A) View from a crystal structure of VNRX-5133 complexed
with NDM-1 (PDB ID: 6RMF) in chain A showing the major observed bicyclic form (yellow). (B) View from a crystal structure of VNRX-5133
complexed with NDM-1 (PDB ID: 6RMF) in chain B showing the tricyclic form (magenta). (C) An overlay of bicyclic (60%, yellow) and tricyclic
(40%,magenta) forms of VNRX-5133 in chains A or B ofNDM-1 and 2mFo-DFc electron density for the tricyclic inhibitor form in chain B (contoured
to 3σ, gray mesh). (D) Proposed mechanism for formation of the unexpected tricyclic VNRX-5133 complex. Enz-Nu = Enz-(ZnII)n-OH (MBL) or
Enz-Ser-OH (SBL). (E) Binding mode of VNRX-5133 to the OXA-10 SBL (PDB ID: 6RTN). (F) Comparison of the binding modes of VNRX-5133
in complex with OXA-10 (PDB ID: 6RTN) in chain A (pale blue) and chain B (pale yellow); omit electron density for the bicyclic form in chain A
(contoured at 3σ, gray mesh).
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inhibitors/substrates,48 is partly disordered in the case of the
VNRX-5133 complex (residues 67−70 and 68−70 could not be
modeled in chains A and B, respectively) and has high B-factors
compared to the rest of the main chain, indicating ﬂexibility.
These observations suggest that the L3 loop may not have an
Figure 4.Overlays of reported bicyclic boronate structures and VNRX-5133 in MBLs, SBLs, and a PBP reveal diﬀerent side-chain orientations. Views
from NDM-1:VNRX-5133 (yellow, bicyclic form, PDB ID: 6RFM), VIM-2:CB2 (teal, PDB ID: 5FQC27), BcII:CB2 (pale green, PDB ID: 5FQB27),
AmpC:CB1 (orange, PDB ID: 6I3029), PBP-2:CB2 (gray, PDB ID: 5J8X27), OXA-10:VNRX-5133 (pale blue, PDB ID: 6RTN), OXA-10:CB1
(brown, PDB ID: 5FQ927), and CTX-M-15:CB1 (wheat, PDB ID: 5T6628). Note that although the crystallographically observed orientations of the
acylamino side chains vary, the binding modes of cyclic ring systems and their carboxylate are conserved, including for VNRX-5133. The acylamino
side chains adopt two broad orientations, reﬂecting binding to SBLs (U-shaped). The VNRX-5133 acylamino side chain adopts clearly diﬀerent
conformations in the bicyclic inhibitor forms in both OXA-10 and NDM-1 structures (Figure 4). Although care should be taken in assuming that the
crystallographically observed binding modes accurately reﬂect the solution behavior, the structural observations imply that the optimized VNRX-5133
side chain can enable potent inhibition of diﬀerent β-lactamase classes, by adopting diﬀerent binding modes. Structural analyses of the cyclic boronates
bound to MBLs and SBLs reveal that the acylamino side chain adopts two types of orientations (at least in the crystalline state), reﬂecting binding to
SBLs orMBLs. These observations imply that there is likely further scope for side chain optimization, including with respect to extending the scope and
potency of MBL inhibition and obtaining more potent (bi/tri)cyclic boronate-based PBP inhibitors. Importantly, comparison of the OXA-10 and
NDM-1 structures with those observed for other structurally related compounds, i.e., CB1/CB2 (which diﬀer from VNRX-5133 only in their C-3
acylamino side chains) when complexed with SBLs (OXA-10,27 CTX-M-15,28 AmpC29), MBLs (NDM-1,27 VIM-2,27 BcII27), and a PBP (PBP-527),
reveal conservation in the binding mode of the bicyclic boronate core (Figure 4). Even allowing for the observed tricycle formation with NDM-1,
similar conformations are observed across all Ambler classes of β-lactamases as well as with a PBP (Figure 4). Superimposition of structures of OXA-
10:VNRX-5133 andNDM-1:VNRX-5133with analogous structures of the respective enzymes with “intermediate” complexes derived from substrates
(e.g., hydrolyzed benzylpenicillin) reveals the binding modes adopted by VNRX-5133/related inhibitors overlap with those adopted by hydrolyzed β-
lactams (Supporting Information Figures S1 and S2B).
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important role in stabilizing VNRX-5133 NDM-1 binding
(Supporting Information Figure S4).
The tricyclic form observed in NDM-1 is probably generated
by the reaction of the acylamino side-chain carbonyl group with
the VNRX-5133 boron, together with associated loss of water/
hydroxide (Figure 3D). Given that we observed evidence for
both the bicyclic and tricyclic forms in the crystal structure
(Figure 3A,B), it seems likely that tricyclization occurs at the
active site, though we cannot rule out the presence of the
tricyclic form at low concentrations in the solution phase.42
Further studies will be necessary to exclude the possibility that
the observed tricyclic inhibitor form is not a crystallization
artifact; it has been proposed that at least one MBL−inhibitor
complex crystal structure, i.e. the mono-zinc carbapenemase
MBL CphA in complex with biapenem, does not necessarily
reﬂect the catalytic pathway in solution.49,50 Nevertheless, the
observation of a tricycle is a striking example of the ability of
boron-based inhibitors to interchange between diﬀerent forms,
potentially giving a tightly bound enzyme−inhibitor complex.
In the case of the OXA-10:VNRX-5133 complex structure
(Figure 3E), the inhibitor is observed to bind similarly in chains
A and B (Figure 3F), with the boron atom covalently linked to
the nucleophilic serine (Ser67), likely mimicking the tetrahedral
intermediate in SBL/MBL catalysis (Figure 1B,C).27,28 The
essential conserved lysine (Lys70),
51 which acts as a general
acid/base, is, at least predominantly, in its carbamylated
(KCX70) form in both chains A and B (Supporting Information
Figure S3). Comparison of this structure with that of OXA-10
complexed with the structurally related bicyclic boronate
inhibitor CB1 (PDB ID: 5FQ927) reveals that, while the bicyclic
cores of both inhibitors manifest similar binding modes, there
are substantial variations in the conformations adopted by their
acylamino side chains, which have implications for the side chain
optimization (Figure 4). The boron-containing bicyclic cores
and the acylamino side chains of both VNRX-5133 and CB1 are
positioned to make hydrophobic/aromatic interactions with
Tyr102 and Met99. Although there is some variation in their
precise conformations, the VNRX-5133 and CB1 aryl
carboxylates are both positioned to make polar interactions
with Gly207 and Arg250 that bind the analogous carboxylates in β-
lactams (Supporting Information Figure S1). Note that some
variations of the aryl carboxylate binding modes are anticipated,
given the diﬀerences in the precise modes of carboxylate binding
employed by diﬀerent classes of SBL/MBL/PBP.
Microbiology. Antimicrobial susceptibility testing of
VNRX-5133 in combination with meropenem (carbapenem)
or cefepime (cephalosporin) was performed in minimal
inhibitory concentration (MIC) antimicrobial assay format
utilizing six clinical isolates of NDM-1-producing clinically
relevant strains of Escherichia coli and Klebsiella pneumoniae
(Table 2). In all cases, the MIC values of cefepime/meropenem
were signiﬁcantly reduced in the presence of VNRX-5133
compared to those in its absence (MIC > 64 μg mL−1). Both
cefepime/VNRX-5133 and meropenem/VNRX-5133 combi-
nations were highly active against all six of the NDM-1-
producing clinical isolates tested, with MIC ranges of 16−0.25
and 1−0.125 μg mL−1, respectively. These results reveal the
potential of VNRX-5133 to act against clinically relevant MBLs
(i.e., NDM-1) in bacteria, consistent with the results from
clinical trials with VNRX-5133.44,45
■ CONCLUSIONS
The overall results clearly support the clinical potential39,52−54
of VNRX-5133 (taniborbactam) for inhibition of MBLs as well
as SBLs, thus potentially extending the current utility of current
β-lactam antibiotics. In this regard, VNRX-5133 is diﬀerent to
the clinically approved boron-containing β-lactamase inhibitor
vaborbactam, which has little activity versus clinically relevant
MBLs.15,26 The coverage of clinically relevantMBLs (and SBLs)
by VNRX-5133, however, is imperfect, with signiﬁcantly lower
or no inhibition being observed for clinically relevant IMP-1, L1,
or OXA-48 (Table 1). There is thus scope for further
optimization of this promising new class of β-lactamase
inhibitors.
The crystallographic results also further imply the potentially
unique properties of boron-containing small molecules to
interchange between diﬀerent binding modes/hybridization
states, thus potentially enabling (more) potent inhibition. It is
possible that bicyclic boronates can bind to SBLs and MBLs in
their sp2 hybridization state, which mimics that of the β-
lactam.23 Once bound at the active site, they can then react with
the SBL nucleophilic serine or MBL-Zn(II)-bridged water/
hydroxide to give a tightly bound sp3 complex, mimicking the
tetrahedral intermediate in catalysis. Note that with the MBLs,
in principle, the sp3 boronate form could bind to the active site,
with a displacement of the “hydrolytic” water/hydroxide from
the active site Zn(II) ions.27−29
The potential of boron to enable further reaction when an
inhibitor is bound to a protein is strikingly evidenced by the
crystallographic observation of the tricyclic form in the case of
NDM-1 (Figure 3B). Further biophysical analyses are required
to demonstrate relevance of the tricyclic inhibitor form in
solution and thus rule out the possibility that the tricyclic
inhibitor form is an artifact arising from the crystallization
conditions. This ability has been exploited in the case of boron
compounds in dynamic combinatorial chemistry55 and is
manifested in the reaction of amidomethylboronic acid
inhibitors with two active site serines in the case of penicillin-
binding protein from Actinomadura sp. R39.56 We propose that
the ability of boron compounds to “morph” between states can
be further exploited in inhibitor/modulator design, especially
where conformational changes during ligand binding are
desirable. Such applications will likely require a combination
of precise activity/binding assays coupled with detailed
biophysical studies.
■ EXPERIMENTAL SECTION
General Procedures. Unless otherwise stated, reactions were
performed under argon using dried glassware and solvents. All
Table 2. Eﬀect of VNRX-5133 on Cefepime/Meropenem
MICs for Selected NDM-1 MBL-expressing
Enterobacteriaceaea
strain species genotype
Cef/MEMMIC
(μg mL−1)
Cef/MEM + VNRX-5133
(10 μg mL−1)
S117 Ec NDM-1 >64 16/1
IR57 Ec NDM-1 >64 8/0.5
B64 Kp NDM-1 >64 0.25/0.25
B68-1 Kp NDM-1 >64 0.5/0.5
IR43 Kp NDM-1 >64 0.5/0.25
91N Ec NDM-1 >64 4/0.125
aEc, Escherichia coli; Kp, Klebsiella pneumoniae; MEM, meropenem;
Cef, cefepime.
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commercially available chemicals, reagents, and solvents were used as
commercially supplied or puriﬁed using appropriate standard
procedures. Petroleum ether (PetEt) refers to distilled light petroleum
of fraction 30−40 °C. A cold bath at−100 °Cwas prepared by addition
of liquid nitrogen to a mixture of 1:1 ethanol/methanol. Reactions were
monitored by thin layer chromatography (TLC) using Merck silica gel
60 F254 aluminum sheets, 5 × 7.5 cm, and using an liquid
chromatography−mass spectrometry (LC−MS) system (Agilent
Technologies 1260 Inﬁnity Series) ﬁtted with a 6120 Quadrupole
mass spectrometer and a Merck Chromolith Performance C18 (100 ×
4.2 mm) HPLC column. TLC analyses were visualized by exposure to
UV irradiation (λmax = 254 or 365 nm) and by dipping the plates in
phosphomolybdic acid, potassium permanganate, or ninhydrin
followed by heating with a heat gun. Chromatographic puriﬁcations
were performed using a Biotage Isolera ﬂash puriﬁcation system with
Biotage prepacked SNAP KP-Sil or SNAP-ULTRA columns and
analytical-grade solvents. 1H, 13C, and 11B NMR spectra were recorded
using Bruker AVIII HD 400, AVIII HD 500, or AVIII 600 instruments
in the solvents indicated. Deuterated solvents were used as supplied.
Chemical shifts (δ), referenced using residual solvent peaks, are
reported in parts per million downﬁeld from tetramethylsilane or
residual solvent peak as internal standard. Multiplicity is given as s
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad),
app (apparent), or a combination of these. Coupling constants, J, are
reported in hertz (Hz) to the nearest 0.5 Hz. COSY, HSQC, and/or
HMBC spectra were utilized to aid the chemical shift assignments
where appropriate. Infrared (IR) spectra were recorded using a Bruker
Tensor 27 FT-IR spectrometer; wavenumbers (νmax) are quoted in
cm−1. Analytical-grade solvents and a PerkinElmer 341 polarimeter
were used for measurement of optical rotations; [α]D
T values are
reported in 10−1 deg cm2 g−1, and concentrations (c) are quoted in g per
100 mL; D refers to the D-line of sodium (589 nm), and temperatures
(T) are given in degrees Celsius (°C). Preparative HPLC was run using
a Shimadzu prep-LC system equipped with an ACE 5 μm C18 column
(100mm× 21.2 mm id). HPLC preparatorymethod A refers to [binary
gradient: 10 mM HCl in water (solvent A), acetonitrile + 25% MeOH
(solvent B), 15 mL min−1] 0−5 min gradient 1% B; 5−30 min gradient
10% B; 31−36 min gradient 90% B, 37−45 min gradient 1% B; UV
detection at 254 nm. Low-resolution mass spectra were recorded using
an Agilent 6120 Quadrupole MS instrument. High-resolution mass
spectra (HRMS) were recorded using a Bruker MicroTOF instrument
with an ESI source and time-of-ﬂight (TOF) analyzer. The LC−MS
system (Agilent Technologies 1260 Inﬁnity Series) was ﬁtted with a
6120 Quadrupole mass spectrometer and a Merck Chromolith
Performance C18 (100 × 4.2 mm) HPLC column. All compounds
synthesized were ≥95% pure as judged by 1H and 13C NMR, LC−MS,
or qHNMR analyses.
tert-Butyl 2-Methoxy-3-methylbenzoate (2). To a solution of 2-
methoxy-3-methylbenzoic acid 1 (2 g, 12.0 mmol, 1 equiv) and
anhydrous N,N-dimethylformamide (5 drops) in anhydrous CH2Cl2
(20 mL) was added oxalyl chloride (1.54 mL, 17.9 mmol, 1.5 equiv)
dropwise under Shlenk conditions. The resultant mixture was stirred at
room temperature (rt) for 90 min, before volatiles were removed in
vacuo. The resulting oil was dissolved in anhydrous 2-methylpropan-2-
ol (30 mL) and stirred at 40 °C for 18 h before the volatiles were
removed in vacuo. H2O (30mL) and CH2Cl2 (60mL) were added, and
the layers were separated. The aqueous layer was extracted with CH2Cl2
(2 × 60 mL). The combined organic layers were washed with brine (30
mL), dried (MgSO4), and then concentrated in vacuo. The crude
material was puriﬁed by ﬂash chromatography (0−30% EtOAc in
cyclohexane) to aﬀord the desired product 2 as a colorless oil (1.70 g,
63%). Rf 0.50 (19:1 CH2Cl2−MeOH); 1H NMR (600 MHz, CDCl3) δ
7.52−7.42 (m, 1H, H-4), 7.25−7.20 (m, 1H, H-2), 6.95 (app t, J = 7.5
Hz, 1H, H-3), 3.75 (s, 3H, H-16), 2.24 (s, 3H, H-9), 1.53 (s, 9H,
C(CH3)3);
13C NMR (101 MHz, CDCl3) δ 166.1 (C-8), 158.0 (C-6),
134.5 (C-2), 132.6 (C-1), 129.0 (C-4), 126.9 (C-5), 123.5 (C-3), 81.4
(C-12), 61.5 (C-16), 28.4 (C(CH3)3), 16.2 (C-9); νmax/cm (neat):
2978, 2360, 1720, 1593, 1468, 1416, 1367, 1169; HRMS (ESI-TOF)
calcd for C13H18O3
23Na [M + Na]+: 245.11482, found: 245.11487.
tert-Butyl 3-(bromomethyl)-2-methoxybenzoate (3). A mixture of
tert-butyl 2-methoxy-3-methylbenzoate 2 (1.69 g, 7.60 mmol, 1 equiv),
N-bromosuccinimide (NBS; 1555 mg, 8.74 mmol, 1.15 equiv), and
benzoyl peroxide (368 mg, 1.52 mmol, 0.2 equiv) in CCl4 (20 mL) was
reﬂuxed in the presence of a Philips HB175 (75W, UV type 3) lamp for
5 h. The reaction mixture was then cooled to rt, the precipitate was
removed by ﬁltration, and the ﬁltrate was concentrated in vacuo. The
crude material was puriﬁed by ﬂash chromatography (0−25%
petroleum ether (PetEt) in cyclohexane) to aﬀord the desired product
3 as a colorless oil (1.33 g, 58%). Rf 0.50 (19:1 CH2Cl2−MeOH); 1H
NMR (400 MHz, CDCl3) δ 7.66−7.60 (m, 1H, H-4), 7.48−7.41 (m,
1H, H-2), 7.04 (app t, J = 8.0 Hz, 1H, H-3), 4.52 (s, 2H, H-9), 3.90 (s,
3H, H-16), 1.54 (s, 9H, C(CH3)3);
13C NMR (151 MHz, CDCl3) δ
165.3 (C=O), 158.2 (C-6), 134.6 (C-2), 132.7 (C-1), 132.3 (C-4),
127.0 (C-5), 123.9 (C-3), 81.9 (C(CH3)3), 62.9 (C-16), 28.3
(C(CH3)3), 27.8 (C-9); νmax/cm (neat): 2979, 2360, 1718, 1591,
1469, 1423, 1080; HRMS (ESI-TOF) calcd for C13H17O3
79Br23Na [M
+ Na]+: 323.02533, found: 323.02542.
tert-Butyl 2-Methoxy-3-(((3aR,4R,6R,7aS)-3a,5,5-trimethylhexa-
hydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)methyl)-
benzoate (4). tert-Butyl 3-(bromomethyl)-2-methoxybenzoate 3 (1.7
g, 5.64 mmol, 1 equiv), bis[(+)-pinanediolato] diboron (2.43 g, 6.80
mmol, 1.2 equiv), and potassium acetate (1108 mg, 98.1 mmol, 2
equiv) were suspended in anhydrous 1,4-dioxane (22.5 mL). The vessel
was degassed for 20 min, and then Pd(dppf)Cl2 (228 mg, 0.28 mmol, 5
mol%) was added. The reaction mixture was reﬂuxed at 95 °C for 16 h
and then concentrated in vacuo. The residue was redissolved in EtOAc
(20mL) and ﬁltered through a Celite pad. The ﬁltrate was concentrated
to dryness under reduced pressure, and the crude material was puriﬁed
by ﬂash chromatography (0−20% EtOAc in cyclohexane) to aﬀord the
desired product as a colorless oil (1.79 g, 87%). Rf 0.70 (15:1 PetEt−
EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.48−7.42 (m, 1H, H-4),
7.28−7.22 (m, 1H, H-6), 6.94 (app t, J = 7.5 Hz, 1H, H-5), 4.20 (dd, J =
9.0, 2.0 Hz, 1H, H-13), 3.74 (s, 3H, H-29), 2.25 (s, 2H, H-24), 2.24−
2.17 (m, 1H, H-15″), 2.13−2.10 (m, 1H, H-12), 1.96 (t, J = 5.5 Hz, 1H,
H-16), 1.84−1.80 (m, 1H, H-15′), 1.77−1.74 (m, 1H, H-11″), 1.52 (s,
9H, C(CH3)3), 1.32 (s, 3H, H-23), 1.21 (s, 3H, H-18), 1.12 (d, J = 10.0
Hz, 1H, H-11′), 0.76 (s, 3H, H-19); 13C NMR (101 MHz, CDCl3) δ
166.2 (C-8), 157.5 (C-2), 134.4 (C-6), 134.1 (C-3), 128.6 (C-4), 126.5
(C-1), 123.5 (C-5), 86.0 (C-13), 81.2 (C(CH3)3), 78.0 (C-14), 61.6
(C-29), 51.4 (C-15), 39.7 (C-12), 39.6 (C-16), 38.3 (C-17), 35.6 (C-
24), 28.7 (C-19), 28.4 (C(CH3)3), 27.2 (C-23), 26.5 (C-11), 24.2 (C-
18); 11B NMR (128MHz, CDCl3) δ 32.8; νmax/cm (neat): 2977, 2918,
2360, 2341, 1721, 1466, 1425. 1367, 1338, 1305, 1279, 1230, 1077,
1028; HRMS (ESI-TOF) calcd for C23H33O5
10B 23Na [M + Na]+:
422.23496, found: 422.23471; [α]D
25 = +15.0° (c 0.8, CHCl3).
tert-Butyl 3-((S)-2-chloro-2-((3aR,4R,6R,7aS)-3a,5,5-trimethyl-
hexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)ethyl)-2-
methoxybenzoate (5). In an oven-dried three-necked round-bottom
ﬂask under an argon ﬂow, a solution of anhydrous CH2Cl2 (0.29 mL,
4.56 mmol, 2.5 equiv) in anhydrous THF (5.5 mL) was cooled to−100
°C. While maintaining a low temperature, n-butyllithium (2.5 M in
hexanes, 1.16 mL, 1.6 equiv) was added slowly dropwise down the
inside wall of the ﬂask (maintaining the temperature below −90 °C at
all times). The resulting turbid white suspension obtained by the
formation of microcrystalline dichloromethyllithium was stirred at
−100 °C for 45 min. Batches that turned black in the above process
(signaling the decomposition of dichloromethyllithium) were imme-
diately quenched with isopropanol and water and discarded. A
precooled (−90 °C) solution of boronic ester 4 (730 mg, 1.82 mmol,
1 equiv) in anhydrous THF (1.2 mL) was then added dropwise at −95
°C. The resulting bright yellow solution was stirred for 20 min at −95
°C, before the freshly prepared anhydrous ZnCl2 solution (0.7 M in
THF, 1.48 mL, 0.8 equiv) was added in one portion. The reaction
mixture was then allowed to warm up slowly to rt overnight without
removal of the cooling bath. The resultant solution was cooled using an
ice bath, quenched with sat. aq NH4Cl solution (20mL), extracted with
EtOAc (3 × 20 mL), washed with brine (15 mL), dried (Na2SO4),
ﬁltered, and then concentrated in vacuo. The crude material was
puriﬁed by ﬂash chromatography (5−50% PetEt in pentane) to aﬀord
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the desired product 5 as a pale yellow oil (500 mg, 61%). Rf 0.55 (20:1
PetEt−EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.62 (dd, J = 7.5, 2.0
Hz, 1H,H-4), 7.39 (dd, J = 7.5, 2.0 Hz, 1H,H-6), 7.05 (app t, J = 7.5Hz,
1H, H-5), 4.35 (dd, J = 9.0, 2.0 Hz, 1H, H-13), 3.85 (s, 3H, H-29),
3.75−3.70 (m, 1H, H-22), 2.26 (dd, J = 14.0, 7.5 Hz, 2H, H-24), 2.25−
2.17 (m, 1H, H-15″), 2.10 (m, 1H, H-12), 1.94−1.90 (m, 1H, H-16),
1.84-1.80 (m, 1H, H-15′), 1.78−1.74 (m, 1H, H-11″), 1.45 (s, 9H,
C(CH3)3), 1.27 (s, 3H, H-23), 1.22 (s, 3H, H-18) 1.19 (d, J = 10.0 Hz,
1H, H-11′), 0.83 (s, 3H, H-19); 13C NMR (126 MHz, CDCl3) δ 166.2
(C-8), 157.8 (C-2), 137.0 (C-6), 134.4 (C-3), 128.6 (C-4), 125.5 (C-
1), 123.5 (C-5), 86.0 (C-13), 81.2 (C-25), 78.0 (C-14), 61.6 (C-29),
51.3 (C-15), 39.6 (C-16), 39.2 (C-17), 35.6 (C-24), 28.7 (C-19), 28.3
(C(CH3)3), 27.2 (C-23), 26.5 (C-11), 24.1 (C-18), C-22 not observed
due to peak broadening; νmax/cm (neat): 2979, 2929, 2359, 2341, 1719,
1466, 1421, 1369, 1303, 1254, 1172, 1135, 767; HRMS (ESI-TOF)
calcd for C24H34O5
10B35Cl23Na [M + Na]+: 470.21164, found:
470.21167; [α]D
25 = −10.0 ° (c 7.6, CHCl3).
tert-Butyl 3-((R)-2-amino-2-((3aR,4R,6R,7aS)-3a,5,5-trimethyl-
hexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)ethyl)-2-
methoxybenzoate (7).To a stirred solution of (S)-chloride 5 (400 mg,
0.89 mmol, 1 equiv) in anhydrous THF (4 mL) under an argon ﬂow
was added a solution of lithium bis(trimethylsilyl)amide (LiHDMS, 1
M in THF, 0.94 mL, 0.94 mmol, 1.05 equiv) dropwise over 30 min at
−100 °C. The resultant mixture was stirred at−78 °C for 2 h before the
volatiles were removed in vacuo. The resultant thick brown oil was
immediately used in the next step without further puriﬁcation. To a
solution of crude bis-TMS-protected amine 6 (500 mg, 0.87 mmol, 1
equiv) in THF (4 mL) was added anhydrous MeOH (2 mL) dropwise
at −10 °C. The resultant cloudy solution was stirred at rt for 60 min
before the volatiles were removed in vacuo. The crude amine 7 thus
obtained as a pale yellow oil was immediately used in the next step
without further puriﬁcation.
Ethyl 2-(trans-4-((2-((tert-butoxycarbonyl)amino)ethyl)-amino)-
cyclohexyl)acetate (9). Ethyl-2-(trans-4-aminocyclohexyl)acetate hy-
drochloride 8 (2 g, 9.04 mmol, 1 equiv) was dissolved in 1:1 CH2Cl2-
H2O (70 mL), and K2CO3 (2740 mg, 20.7 mmoL, 2.3 equiv) was
added. The resultant biphasic suspension was vigorously stirred at rt for
60 min, before benzyltriethylammonium chloride (103 mg, 0.45 mmol,
5 mol%) and 2-(Boc-amino)ethyl bromide (2100 mg, 9.37 mmol, 1.04
equiv) were added in one portion. The reactionmixture was reﬂuxed for
18 h, before it was poured into sat. aq NH4Cl (70 mL). The layers were
separated, and the aqueous layer was extracted with CH2Cl2 (3 × 70
mL). The combined organic layers were washed with brine (70 mL),
dried (MgSO4), then concentrated in vacuo. The crude material was
puriﬁed by ﬂash chromatography (0−20%MeOH in CH2Cl2) to aﬀord
the desired product 9 as a white solid (1.45 g, 49%). Rf 0.80 (1:1
EtOAc−pentane); mp 118−120 °C; 1H NMR (600 MHz, CDCl3) δ
5.00 (br s, 1H, Boc-NH), 4.05 (q, J = 7.0 Hz, 2H, -OCH2CH3),
3.18−3.04 (m, 2H, CH2), 2.74−2.61 (m, 2H, CH2), 2.39−2.24 (m, 1H,
CH), 2.11 (d, J = 7.0 Hz, 2H, CH2), 1.90−1.82 (m, 2H, CH2),
1.80−1.59 (m, 3H, CH2 + CH), 1.37 (s, 9H, C(CH3)3), 1.18 (t, J = 7.0
Hz, 3H, -OCH2CH3), 1.11−1.03 (m, 2H, CH2), 0.99−0.92 (m, 2H,
CH2);
13C NMR (151 MHz, CDCl3) δ 173.1 (-NH-C=O), 156.3
(C=O), 79.3 (C(CH3)3), 60.3 (-CO2CH2CH3), 56.6 (CH), 46.4
(CH2), 41.8 (CH2), 34.7 (CH), 33.3 (CH2), 31.7 (CH2), 28.6
(C(CH3)3), 14.4 (-CO2CH2CH3); νmax/cm (neat): 3348, 2953, 2851,
1731, 1711, 1520, 1450, 1391, 1282, 1249, 1172, 1032; HRMS (ESI-
TOF) calcd for C17H33O4N2 [M + H]
+: 329.24348, found: 329.24289.
Ethyl 2-(trans-4-((tert-butoxycarbonyl)(2-((tert-butoxycarbonyl)-
amino)ethyl)amino)cyclohexyl)acetate (10). Ethyl 2-(trans-4-((2-
((tert-butoxycarbonyl)amino)ethyl)amino)cyclohexyl)acetate 9 (1.4 g,
4.26 mmol, 1 equiv) was dissolved in anhydrous CH2Cl2 (37 mL)
before di-tert-butyl dicarbonate (2326 mg, 10.7 mmol, 2.5 equiv) and
N,N-diisopropylethylamine (1.11 mL, 6.39 mmol, 1.5 equiv) were
added. The reaction mixture was reﬂuxed for 16 h, before the volatiles
were removed in vacuo. The residue thus obtained was resuspended in
CH2Cl2 (30 mL), and sat. aq NH4Cl (50 mL) was added. The layers
were separated, and the aqueous layer was extracted with CH2Cl2 (3 ×
70 mL). The combined organic layers were dried (MgSO4), then
concentrated in vacuo. The crude material was puriﬁed by ﬂash
chromatography (0−20% MeOH in CH2Cl2) to aﬀord the desired
product 10 as a yellow oil (1.50 g, 82%). Rf 0.90 (1:1 EtOAc−pentane);
1H NMR (400 MHz, CDCl3) δ 4.11 (q, J = 7.0 Hz, 2H, -OCH2CH3),
3.31−3.10 (m, 4H, CH2), 2.17 (d, J = 7.0 Hz, 2H, CH2), 1.86−1.58 (m,
5H, CH2 +CH), 1.65−1.32 (m, 19H, C(CH3)3) +CH), 1.25 (t, J = 7.0,
3.0 Hz, 3H, -OCH2CH3), 1.17−0.99 (m, 2H, CH2); 13C NMR (101
MHz, CDCl3) δ 172.8 (-NH-C=O), 156.4 (C=O), 156.1 (C=O), 79.9
(C(CH3)3), 60.2 (-CO2CH2CH3), 42.5 (CH2), 41.6 (CH), 41.0
(CH2), 34.0 (CH), 32.2 (CH2), 30.3 (CH2), 28.5 (C(CH3)3), 28.4
(C(CH3)3), 14.3 (-CO2CH2CH3); νmax/cm (neat): 3367, 2978, 2931,
1715, 1689, 1516, 1453, 1408, 1391, 1248, 1170; HRMS (ESI-TOF)
calcd for C22H41O6N2 [M + H]
+: 429.29591, found: 429.29582.
2-(trans-4-((tert-Butoxycarbonyl)(2-((tert-butoxycarbonyl)-
amino)ethyl)amino)cyclohexyl)acetic Acid (11). Ethyl ester 10 (1604
mg, 3.74mmol, 1 equiv) was dissolved in 1:2:1mixture of THF/EtOH/
H2O (10 mL), and LiOH·H2O (224 mg, 9.36 mmol, 2.5 equiv) was
added. The resultant cloudy solution was stirred at rt for 5 h before the
volatiles were removed in vacuo. The residue thus obtained was
dissolved in minimum amount of water and ﬁltered through a short
column ofAmberlite IR-120 (H+ form). To the obtained aqueous ﬁltrate
was added EtOAc (50 mL), and the layers were separated. The aqueous
layer was extracted with EtOAc (3 × 50 mL), washed with brine (20
mL), dried (Na2SO4), and then concentrated in vacuo to aﬀord the
desired product 11 as a shiny white solid (1 g, 67%). Rf 0.45 (1:1
EtOAc−pentane); mp 97−98 °C; 1H NMR (500 MHz, CDCl3) δ
3.36−3.12 (m, 4H, CH2), 2.25 (d, J = 7.0 Hz, 2H, CH2), 1.93−1.86 (m,
2H, CH2), 1.80−1.70 (m, 3H, CH2 + CH), 1.68−1.33 (m, 21H,
C(CH3)3 + CH2 + CH), 1.20−1.06 (m, 2H, CH2); 13C NMR (126
MHz, CDCl3) δ 178.5 (C=O), 177.0 (C=O), 80.1 (C(CH3)3), 80.0
(C(CH3)3), 41.1 (CH2), 33.7 (CH), 32.1 (CH2), 30.3 (CH2), 28.5
(C(CH3)3), 28.4 (C(CH3)3), 20.7; νmax/cm (neat): 3055, 3009, 2974,
2930, 1706, 1686, 1672, 1518, 1477, 1409, 1365, 1247, 1023; HRMS
(ESI-TOF) calcd for C20H37O6N2 [M + H]
+: 401.26461, found:
401.26401.
tert-Butyl 3-((R)-2-(2-(trans-4-((tert-butoxycarbonyl)(2-((tert-
butoxycarbonyl)amino)ethyl)amino)cyclohexyl)acetamido)-2-
((3aR,4R,6R,7aS)-3a,5,5-trimethylhexahydro-4,6-methanobenzo-
[d][1,3,2]dioxaborol-2-yl)ethyl)-2-methoxybenzoate (12). To a
solution of carboxylic acid 11 (416 mg, 1.04 mmol, 1.2 equiv) in
anhydrous CH2Cl2 (2.60 mL) were added triethylamine (0.36 mL, 2.61
mmol, 3 equiv), benzotriazol-1-yl-oxytripyrrolidinophosphonium
hexaﬂuorophosphate (PyBOP; 541 mg, 1.04 mmol, 1.2 equiv), and
crude amine 7 (325 mg, 0.87 mmol, 1 equiv). The resultant solution
was stirred at rt for 75 min before water (10 mL) was added, and the
layers were separated. The aqueous layer was extracted with CH2Cl2 (3
× 10 mL). The combined organic layers were washed with brine (10
mL), dried (MgSO4), then concentrated in vacuo. The crude material
was puriﬁed by ﬂash chromatography (0−20% MeOH in CH2Cl2).
Although several impurities were still present after this step (as judged
by 1HNMR and LC−MS), the amide 12 thus obtained as a yellow foam
(224 mg, 34%) was used in the next step without further puriﬁcation. Rf
0.55 (1:2 EtOAc−pentane); 1HNMR (500MHz,MeOD) δ 7.61−7.49
(m, 1H, Ar), 7.46−7.35 (m, 1H, Ar), 7.13−7.09 (m, 1H, Ar), 4.22−
4.14 (m, 1H, CHOB), 3.80 (s, 3H, −OCH3), 3.21−3.10 (m, 4H,
−NCH2CH2NHBoc), 2.94−2.85 (m, 2H, CHB + Ar-CH2), 2.75−2.67
(m, 1H, Ar-CH2), 2.38−2.30 (m, 1H, pinanediol-CH2), 2.26 (d, J = 7.0
Hz, 2H, -CHCH2CO), 2.12−2.06 (m, 1H, pinanediol-CH2), 2.01 (s,
1H, cyclohexyl-CH), 1.94 (app t, J = 5.5 Hz, 1H, pinanediol-CH),
1.90−1.79 (m, 5H, cyclohexyl-CH2 + pinanediol-CH), 1.76−1.66 (m,
3H, cyclohexyl-CH2 + cyclohexyl-CH), 1.64−1.58 (m, 11H, -CO2C-
(CH3)3 + cyclohexyl-CH2), 1.40−1.36 (s, 10H, C(CH3)3 + pinanediol-
CH2), 1.43 (s, 9H, C(CH3)3), 1.37 (s, 3H, CH3), 1.28 (s, 3H, CH3),
1.18−1.08 (m, 2H, cyclohexyl-CH2), 0.89 (s, 3H, CH3); 13C NMR
(126 MHz, MeOD) δ 174.9, 173.0, 170.3, 158.4, 157.3, 144.1, 141.5,
133.2, 131.1, 130.3, 126.5, 125.6, 124.7, 81.2, 80.0, 78.4, 69.9, 61.5,
59.8, 55.3, 52.9, 51.9, 42.0, 41.8, 40.8, 38.7, 36.8, 35.2, 33.2, 30.1, 29.1,
29.0, 28.8, 28.7, 28.4, 28.4, 27.5, 27.2, 24.6, 24.3, 20.9, 14.5; νmax/cm
(neat): 3627, 3599, 2987, 2864, 2360, 1701, 1692, 1592, 1466, 1454,
1305, 1277, 1136; HRMS (ESI-TOF) calcd for C44H71O10N3
10B [M +
H]+: 811.52633, found: 811.52667.
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(R)-3-(2-(trans-4-((2-Aminoethyl)amino)cyclohexyl)acetamido)-
2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic
Acid (13). To a precooled (−78 °C) solution of boronate 12 (50 mg,
0.06mmol, 1 equiv) in anhydrous CH2Cl2 (1mL) was added BCl3 (1M
in CH2Cl2, 0.31 mL, 5 equiv) dropwise over 20 min. The reaction
mixture was stirred for 60 min, then water (5 mL) was added, and the
layers were separated. The organic layer was extracted with water (3× 5
mL). The combined aqueous layers were lyophilized to aﬀord the crude
product as a brown solid. Following challenging puriﬁcation via HPLC
preparatory method A, the desired product 13 was obtained as a white
solid (10 mg, 42%). The relatively low yield may reﬂect deborylation
during puriﬁcation as suggested by LC−MS analyses of the collected
fractions. Purity: ≥96% by qHNMR. Rf baseline (1:1 CH2Cl2−
MeOH); 1H NMR (600MHz, D2O) δ 7.84−7.75 (m, 1H, H-4), 7.47−
7.37 (m, 1H, H-6), 7.06 (app t, J = 8.0Hz, 1H,H-5), 3.34−3.29 (m, 4H,
H-33, H-34), 3.28−3.22 (m, 1H, H-9), 3.00−2.88 (m, 2H, H-8), 2.82−
2.71 (m, 1H, H-23), 2.34−2.27 (m, 1H, H-19′), 2.14−2.04 (m, 1H, H-
19″), 1.88−1.73 (m, 2H, CH2-27/CH2-29), 1.43−1.37 (m, 1H, CH2-
26/CH2-30), 1.35−1.26 (m, 1H, H-25), 1.20−0.90 (m, 2H, CH2-27/
CH2-29), 0.86−0.75 (m, 1H, CH2-26/CH2-30), 0.68−0.38 (m, 2H,
CH2-26/CH2-30);
13C NMR (151 MHz, D2O) δ 179.3 (C-10), 169.93
(C-3), 156.4 (C-1), 136.6 (C-6), 129.7 (C-4), 128.7 (Ar-C), 121.9 (C-
5), 116.7 (Ar-C), 56.9 (C-23), 41.1 (C-33/C-34), 35.6 (C-33/C-34),
35.5 (C-19), 33.6 (C-25), 30.5 (C-8), 28.9 (C-26/C-30), 28.4 (C-26/
C-30), 28.1 (C-27/C-39), 28.0 (C-27/C-39), C-9 not observed due to
peak broadening; HRMS (ESI-TOF) calcd for C19H29O5N3
10B [M +
H]+: 389.22311, found: 389.22333.
Inhibition Assays. Inhibitory activity of VNRX-5133 against
representative SBLs and MBLs was determined using a ﬂuorogenic
assay monitoring the enzymatic breakdown of the cephalosporin probe
FC5,38 with the exception of the subclass B2 MBL CphA, for which the
hydrolysis of meropenem substrate was used.27 The FC5/meropenem
assays were conducted at room temperature in clear-bottomed Greiner
384 black well microplates (FC5) or Greiner 96 well UV star
microplates (meropenem), using a ClarioStar or PHERAstar FS
microplate reader (BMG LabTech). Representative β-lactamases were
tested at the following concentrations: AmpC, 500 pM; OXA-10, 250
pM; OXA-48, 12.5 nM; TEM, 1 nM; VIM-1, 100 pM; NDM-1, 20 pM;
IMP-1, 20 pM; VIM-2, 500 pM; and L1, 50 pM. The concentration of
FC5 employed was 10 μM for TEM-1 and 5 μM for all other enzymes.
The concentration of meropenem used was 12.5 μM for CphA. TEM-
116, AmpC, OXA-10, and OXA-48 inhibition assays were run in “SBL
buﬀer” (phosphate buﬀer, pH 7.4, 0.01% (v/v) Triton X-100), while
IMP-1, VIM-1, VIM-2, NDM-1, NDM-2, L1, and CphA were screened
in “MBL buﬀer” (50 mM HEPES, pH 7.2, 1 μM ZnSO4, 1 μg mL
−1
BSA, 0.01% v/v Triton X-100). OXA-10 and OXA-48 assays were also
run in “SBL buﬀer” supplemented with 100 mM NaHCO3. The initial
rates of reaction (measured after 10 min pre-incubation of VNRX-5133
with the enzyme) were assessed by monitoring the ﬂuorescence
intensity at λex = 380 nm and λem = 460 nm, except for B2 MBL CphA,
where UV absorbance was monitored at λ = 300 nm. Following the
determination of initial rates of reaction, the data were ﬁtted using a
four-parameter function: log (inhibitor) vs. response, variable slope in
GraphPad Prism 6 (Supporting Information Table S1) to obtain IC50
values.
Antimicrobial Susceptibility Testing. Meropenem (MEM) and
cefepime (Cef) were tested alone (0.06−64 μg mL−1) and in
combination with bicyclic boronate VNRX-5133 (10 μg mL−1) against
a small set of NDM-1-producing Enterobacteriaceae (Table 2), in
triplicate. Minimal inhibitory concentration (MIC) values were
determined by the agar dilution method and interpreted using
published guidelines described by EUCAST/CLSI.57 All reported
MIC values are within ±1 log2 dilution of the reference MIC values.
Crystallization Experiments, X-ray Data Collection, and
Processing. NDM-1 was cloned and puriﬁed as previously
described.28 Crystallization experiments were set up using a solution
of OXA-10 (8.5 mg mL−1) in 50 mMMES, pH 6.0; 100 mMNaCl; and
NDM-1 (30 mg mL−1) in 20 mM Tris, pH 8.0; 150 mM NaCl; and 2
mM DTT. OXA-10 crystals were supplemented with 10 mM VNRX-
5133. OXA-10 crystallization was performed at room temperature using
the sitting drop vapor diﬀusion method. Crystals were obtained using
100 μL of reservoir solution, i.e. 200 mM Zn(OAc)2·2H2O, 100 mM
imidazole, 20% PEG 3000, pH 8.0, and a 1:1 mixture (0.2 μL:0.2 μL) of
protein/reservoir solution in the crystallization drop. Crystals were
cryoprotected using well solution diluted to 25% (v/v) aqueous
glycerol and harvested with nylon loops and subsequent ﬂash-cooling in
liquid nitrogen.
NDM-1 was crystallized by sitting drop vapor diﬀusion in CrysChem
24-well plates (Hampton Research) at 19 °C, with micro seeding.
Protein (2 μL) was mixed with 1.5 μL of the reservoir solution (32%
PEG3350, 0.1 M Bis-Tris, pH 5.8, 0.15 M NH4SO4) and 0.5 μL of
crystal seed. Crystals were then soaked by addition of 2 mM VNRX-
5133 directly to the drop for 4 h. Crystals were then cryoprotected by
brief exposure to 20% (v/v) aqueous glycerol (in well solution) and
subsequently ﬂash-cooled in liquid nitrogen.
Diﬀraction data for OXA-10 and NDM-1 were collected at 100 K at
beamlines I04 and I24, respectively, of the Diamond Light Source,
Didcot. OXA-10 diﬀraction data were integrated and scaled using
autoPROC. NDM-1 data were integrated in DIALS and scaled in
Aimless. The structures were solved by isomorphous molecular
replacement using reported NDM-1 (PDB accession code: 3SPU58)
and OXA-10 (PDB accession code: 5FQ927) as search models. Both
structures were then iteratively ﬁtted and reﬁned using PHENIX59 and
Coot.60 Processing and reﬁnement statistics for NDM-1 and OXA-10
with VNRX-5133 can be found in Supporting Information Table S3.
Molprobity validation reports for OXA-10 and NDM-1 structures are
available in Supporting Information Tables S4 and S5, respectively.
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